As the RNA interference technique and monoclonal antibody clinical therapeutic application, nanovesicle delivery system packaged with siRNAs or other targeting PTPRM drugs might exert potential anti-tumor role in CCa treatment in the future. Here, PTPRM is linked to neoplasm.